CSF2 and myeloid sarcoma: Clinical use of daclizumab, an anti-IL-2Rα monoclonal antibody, showed efficacy in reducing inflammatory activity in relapsing multiple sclerosis (MS) by limiting GM-CSF secretion 124, 125.